RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-2.4%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.42B
AUM Growth
+$1.42B
(-3.3%)
Cap. Flow
+$25.4M
Cap. Flow
% of AUM
1.79%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
97
New
3
Increased
35
Reduced
20
Closed
5
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$31.5M |
| 2 |
Pfizer
PFE
|
$21.5M |
| 3 |
Biogen
BIIB
|
$17M |
| 4 |
McKesson
MCK
|
$14M |
| 5 |
Elevance Health
ELV
|
$9.32M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.82% |
| 2 | Industrials | 1.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $51.5M | 3.61% | 470,000 -55,000 | -10% | -$6.02M |
|
2
UnitedHealth
UNH
$281B
| $48.8M | 3.43% | 125,000 | – | – |
|
|
3
Elevance Health
ELV
$71.8B
| $44.7M | 3.14% | 120,000 +25,000 | +26% | +$9.32M |
|
|
4
Johnson & Johnson
JNJ
$427B
| $43.6M | 3.06% | 270,000 +195,000 | +260% | +$31.5M |
|
|
5
Pfizer
PFE
$141B
| $43M | 3.02% | 1,000,000 +500,000 | +100% | +$21.5M |
|
|
6
Biogen
BIIB
$19.4B
| $42.4M | 2.98% | 150,000 +60,000 | +67% | +$17M |
|
7
AbbVie
ABBV
$372B
| $38.3M | 2.69% | 355,000 +35,000 | +11% | +$3.78M |
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $36.5M | 2.56% | 280,000 +60,000 | +27% | +$7.81M |
|
9
Thermo Fisher Scientific
TMO
$186B
| $34.3M | 2.41% | 60,000 +10,000 | +20% | +$5.71M |
|
10
Medtronic
MDT
$119B
| $34.2M | 2.4% | 273,000 | – | – |
|
11
CVS Health
CVS
$92.8B
| $33.9M | 2.38% | 400,000 +20,000 | +5% | +$1.7M |
|
12
Eli Lilly
LLY
$657B
| $33.5M | 2.35% | 145,000 +26,200 | +22% | +$6.05M |
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $29.9M | 2.1% | 165,000 -50,897 | -24% | -$9.23M |
|
|
14
McKesson
MCK
$85.4B
| $29.5M | 2.07% | 148,000 +70,000 | +90% | +$14M |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26.5M | 1.86% | 150,000 -15,000 | -9% | -$2.65M |
|
16
Guardant Health
GH
$8.41B
| $25.6M | 1.8% | 205,000 +30,000 | +17% | +$3.75M |
|
17
Cigna
CI
$80.3B
| $25.4M | 1.78% | 127,000 -3,500 | -3% | -$701K |
|
18
Boston Scientific
BSX
$156B
| $24.7M | 1.74% | 570,000 +50,000 | +10% | +$2.17M |
|
19
Abbott
ABT
$231B
| $24.3M | 1.71% | 206,000 -44,000 | -18% | -$5.2M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $22.9M | 1.61% | 135,000 -22,925 | -15% | -$3.89M |
|
|
ABMD
21
DELISTED
Abiomed Inc
ABMD
| $22.8M | 1.6% | 70,000 +5,000 | +8% | +$1.63M |
|
22
Merck
MRK
$210B
| $22.5M | 1.58% | 300,000 | – | – |
|
23
Cencora
COR
$56.5B
| $22.5M | 1.58% | 188,000 +15,000 | +9% | +$1.79M |
|
24
Humana
HUM
$36.5B
| $22.2M | 1.56% | 57,000 +2,000 | +4% | +$778K |
|
25
Gilead Sciences
GILD
$140B
| $21M | 1.47% | 300,000 | – | – |
|